Parlux reports lower Q2 as profits and sales slide

By Simon Pitman

- Last updated on GMT

Related tags Company Stock

Parlux has reported another disappointing quarter, with profits
falling 20 per cent against a slight slip in sales, as lower
margins and royalty payments bite hard.

The company said that sales for the quarter ending September 30 were approximately $39.1m, compared to sales of $39.3m for the same period last year, a fall of around 1 per cent.

Net income came in at $3.5m, down from $4.4m, which, as well as being attributed to lower royalties for non-fragrance products, was also blamed on duplicated warehouse and temporary storage expenses, as well as additional interest expenses.

The company also added that some of the costs were offset by a $1.8m gain from the sale of its investment in E com Ventures, a company that is owned by Parlux stakeholder Glen Nussdorf.

Nussdorf has stated his opposition to recent executive board decisions at Parlux and had tried to launch a take-over bid for the company in October last year.

Net sales for the six month period to September 30 came in at $79.8m, compared to $73.1m for the same period a year earlier - an increase of 9 per cent.

For the same period the company reported a net loss of $10.6m, compared to a net profit of $8.3m a year earlier. It said that this figure was largely attributable to a $16.2m compensation charge relating to outstanding warrants issued as a result of a stock split.

The company also said that a review of its financial results for the period ending September 30 , 2006, will be delayed. Although it did not specify a date for its publication, the company blamed a class action suit filed against it on November 8 by shareholders regarding its accountancy practices as the reason for the delay.

Meanwhile, the board of directors says it has authorized a stock buy-back program, that will involve the sale of up to ten million company shares, in step with successive buy-back schemes that have been initiated during the course of the past ten years.

Further to this, a date of February 1, 2007, has been given for NASDAQ to respond to the company's request for a hearing before a panel regarding the filing of the company's previous quarterly results, up to June 30, 2006.

Related topics Skin Care Fragrance

Related news

Show more

Related products

show more

See our latest innovations in personal care

See our latest innovations in personal care

Content provided by Covation Bio™ PDO | 02-Apr-2024 | White Paper

At CovationBio PDO, we’re helping the world achieve its sustainability goals by enabling better performing, better-for-the planet products across a range...

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers

Follow us


View more


Beauty 4.0 Podcast